The Oligonucleotide Therapeutics Society (OTS) is an open, nonprofit forum to foster research and development of oligonucleotide therapeutics.
The Founders’ vision was to bring together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential. A new era of oligonucleotide drugs was envisioned that would change the landscape of therapeutic modalities.
Oligonucleotide therapeutics are now being used to successfully treat diseases and have the potential for widespread application. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. Incredibly, oligonucleotide therapeutics have also been used to create an individualized treatment for one single person with a rare, fatal disease.
All the latest news
Investigating the Biology and Potential of CircRNA
In the past few years, mRNA has become a mainstream word with the swift creation of mRNA vaccines to ...
Hydrogels and Nucleic Acids – An Innovative Combination
An incredible amount of time, effort, and money have gone into finding increasingly better ways to safely and effectively deliver ...
The Oligonucleotide Therapeutics Society is Pleased to Announce the 2023 Annual Meeting in Barcelona, Spain
The Oligonucleotide Therapeutics Society (OTS) is excited to bring together those in the field of oligonucleotide therapeutics for its ...
Featured Member
Leonora Abdullahu, PhD
Genetic Medicines Search and Evaluation
Eli Lilly & Company
What’s special about the work I’m currently doing in External Innovation at Eli Lilly, is that it allows us to partner with biotech’s in the field that have assets aligned with Lilly’s strategic goals and internal discovery efforts, and provide them with the resources and expertise to bring those assets to the market. This really expedites the drug discovery process, allowing us to make leaps instead of steps!
